• Consensus Rating: Buy
  • Consensus Price Target: $3.67
  • Forecasted Upside: 605.13%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$0.52
▲ +0.0427 (8.95%)

This chart shows the closing price for XAIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beyond Air Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XAIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XAIR

Analyst Price Target is $3.67
▲ +605.13% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Beyond Air in the last 3 months. The average price target is $3.67, with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 605.13% upside from the last price of $0.52.

This chart shows the closing price for XAIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Beyond Air. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/9/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/7/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/5/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/3/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/3/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/1/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/30/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/16/2024Roth CapitalUpgradeStrong-Buy
8/16/2024Roth MkmReiterated RatingBuy$2.00
8/7/2024Piper SandlerLower TargetOverweight ➝ Overweight$3.50 ➝ $1.00
6/25/2024Piper SandlerLower TargetOverweight ➝ Overweight$7.00 ➝ $3.50
6/25/2024BTIG ResearchDowngradeBuy ➝ Neutral
4/30/2024Truist FinancialLower TargetBuy ➝ Buy$10.00 ➝ $8.00
11/14/2023Truist FinancialLower TargetBuy ➝ Buy$14.00 ➝ $10.00
7/28/2023Piper SandlerInitiated CoverageOverweight$10.00
7/21/2023Truist FinancialLower TargetBuy$18.00 ➝ $14.00
6/23/2023OppenheimerLower Target$16.00 ➝ $10.00
6/15/2023BTIG ResearchInitiated CoverageBuy$15.00
6/29/2022Truist FinancialBoost TargetBuy$16.00 ➝ $20.00
6/29/2022LADENBURG THALM/SH SHBoost TargetBuy$17.00 ➝ $23.00
11/15/2021Roth CapitalBoost TargetBuy$11.00 ➝ $15.00
11/12/2021Truist FinancialBoost TargetBuy$12.00 ➝ $16.00
11/12/2021OppenheimerBoost TargetOutperform$9.00 ➝ $13.00
6/22/2021Roth CapitalReiterated RatingBuyC$11.00
6/22/2021LADENBURG THALM/SH SHReiterated RatingBuyC$17.00
6/18/2021OppenheimerReiterated RatingBuy$9.00
6/15/2021Roth CapitalReiterated RatingBuy
4/28/2021Truist FinancialInitiated CoverageBuy$12.00
9/22/2020OppenheimerReiterated RatingBuy$9.00
6/23/2020OppenheimerReiterated RatingBuy$9.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/3/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/3/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/2/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/31/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Beyond Air logo
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Read More

Today's Range

Now: $0.52
Low: $0.49
High: $0.58

50 Day Range

MA: $0.39
Low: $0.30
High: $0.48

52 Week Range

Now: $0.52
Low: $0.30
High: $2.61

Volume

1,244,443 shs

Average Volume

543,362 shs

Market Capitalization

$24.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Beyond Air?

The following sell-side analysts have issued stock ratings on Beyond Air in the last year: BTIG Research, Piper Sandler, Roth Capital, Roth Mkm, and Truist Financial Co..
View the latest analyst ratings for XAIR.

What is the current price target for Beyond Air?

3 Wall Street analysts have set twelve-month price targets for Beyond Air in the last year. Their average twelve-month price target is $3.67, suggesting a possible upside of 668.2%. Truist Financial Co. has the highest price target set, predicting XAIR will reach $8.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $1.00 for Beyond Air in the next year.
View the latest price targets for XAIR.

What is the current consensus analyst rating for Beyond Air?

Beyond Air currently has 1 hold rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XAIR will outperform the market and that investors should add to their positions of Beyond Air.
View the latest ratings for XAIR.

What other companies compete with Beyond Air?

Other companies that are similar to Beyond Air include PAVmed, Modular Medical, Hyperfine, TELA Bio and Vivani Medical. Learn More about companies similar to Beyond Air.

How do I contact Beyond Air's investor relations team?

Beyond Air's physical mailing address is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. The company's listed phone number is (516) 665-8200. The official website for Beyond Air is www.beyondair.net. Learn More about contacing Beyond Air investor relations.